Introduction
============

Dual antiplatelet therapy (DAPT), with aspirin and a P2Y~12~-receptor inhibitor, is a basis for the care of patients after percutaneous coronary intervention (PCI).[@ref1] [@ref2] [@ref3] The recommended duration of DAPT for patients after drug-eluting stent (DES) implantation is ≥12 months for patients with acute coronary syndrome (ACS), and six months for patients with stable coronary artery disease.[@ref2] [@ref3] Despite these recommendations, the optimal timing of switching from DAPT to a single antiplatelet therapy continues to be a matter of debate, owing to refinements in DES technologies and the advent of potent P2Y~12~receptor inhibitors.[@ref4]

The recommendation for ≥12 months of DAPT after PCI with DES has received scrutiny by several randomised controlled trials, which proved non-superiority compared with three to six months of DAPT.[@ref5] [@ref6] [@ref7] [@ref8] [@ref9] Furthermore, shorter durations, as opposed to longer durations of DAPT, were associated with lower rates of all cause mortality as a result of lower rates of bleeding-related deaths.[@ref10] Nevertheless, the wide non-inferiority margins of up to six months of DAPT from single randomised controlled trials have prevented researchers from concluding that short term DAPT could replace the conventional standard duration. Additionally, a recent individual patient data meta-analysis of six randomised controlled trials suggested that three months of DAPT was associated with an increased risk of ischemia in patients with ACS.[@ref11]

Coronary artery disease is a leading cause of reduced health globally, as well as in each world region.[@ref12] A cost effectiveness analysis of different durations of DAPT after PCI with DES showed that three to six months of DAPT was better than ≥12 months of DAPT.[@ref13] Moreover, DAPT disruption owing to non-compliance or bleeding, which is more frequent with longer durations of DAPT, increases the risk of adverse events.[@ref14] Thus, shortening the recommended duration of DAPT might relieve the global health burden. However, previous studies have focused on comparing two arms representing longer or shorter durations of DAPT when investigating the efficacy and safety of the discontinuation of DAPT after PCI with DES.[@ref15] [@ref16] [@ref17] [@ref18] Without more quantified criteria for various durations, it would be unlikely to make a strong inference regarding rationality of up to six months of DAPT based on the current evidence. Additionally, the limited head-to-head trials might weaken the conclusiveness of pairwise meta-analysis and network meta-analysis results with small sample sizes or unsuitable arms.

Therefore, we performed this network meta-analysis to better quantify durations of DAPT and make full use of direct and indirect evidence to provide a more comprehensive evaluation with more precise results.[@ref19] Here, we concentrated on both the general population of coronary artery disease and subgroups (eg, patients with ACS) to increase the universality of the conclusions.

Methods
=======

The detailed protocol, which followed the template of a Cochrane review for multiple interventions is available in the PROSPERO registry (CRD42018099519).[@ref20] This systematic review was prepared according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) and the PRISMA extension statement for network meta-analysis.[@ref21] [@ref22]

Search strategy and selection criteria
--------------------------------------

We conducted a systematic search of the literature in April 2018. The databases included Medline, Embase, Cochrane Library for clinical trials, PubMed, and Web of Science. We also searched ClinicalTrials.gov and Clinicaltrialsregister.eu. The MeSH search terms included the following: drug eluting stents, percutaneous coronary intervention, platelet aggregation inhibitors, antiplatelet therapy, and aspirin. Our search strategy was tailored to each database (appendix 1).

We included randomised controlled trials that met the following criteria: participants were adults (aged ≥18) who received DAPT after PCI with DES; the interventions were candidate durations of DAPT (that is, short term (≤6 months), standard term (12 months), and long term (\>12months) DAPT); comparisons with another candidate duration were made; or the outcomes included death, myocardial infarction, stroke, and bleeding.

We excluded studies that met the following criteria: ≤1 month of DAPT, analyses of non-randomised trials, cross-sectional studies, case reports or case series, ongoing trials, or insufficient data from original studies.

The prespecified efficacy endpoints included all cause mortality, cardiac death, non-cardiac death, myocardial infarction, stroke, definite or probable stent thrombosis, and net adverse clinical events. The safety endpoint included major bleeding and any bleeding. The endpoint definitions applied in each trial (table B in appendix 3) were incorporated.

Data extraction and risk of bias assessment
-------------------------------------------

For each eligible randomised controlled trial, we extracted the study characteristics (eg, trial registration number, year of publication, first author, arms and treatment regimens, follow-up time, number of intention-to-treat patients, region), patient characteristics (eg, proportions of patients with ACS or diabetes, mean age), and outcome measures (table B in appendix 3). The reviewers independently screened the titles and abstracts of the retrieved studies in pairs (SHLY, PX, BW, HY) to exclude any that did not research the question of interest. Pairs of reviewers (SHLY, PX, BW, HY) then independently screened full texts of the remaining articles to identify studies that met all of the criteria for inclusion in the quantitative synthesis. We manually checked the reference list of each acquired article for relevant studies. For qualified trials, the data were extracted independently by pairs of reviewers (SHLY, PX, BW, HY), and the discrepancies were resolved by a third reviewer.

The quality of the included studies was assessed according to the Cochrane Collaboration's tool for assessing the risk of bias.[@ref23] Any discrepancies were resolved by consensus, referring to the original articles and consulting with a third reviewer.

Data synthesis and statistical analysis
---------------------------------------

We applied odds ratios and 95% confidence intervals to summary statistics to quantify the effects of different durations. Odds ratios greater than one represented an efficacy or safety benefit favouring the control duration. Two sided P\<0.05 was considered significant.

We used a frequentist approach to conduct network meta-analyses, because of the complete graphical tools that depict the network geometry. We assumed a common heterogeneity variance across all pairwise comparisons and used the between studies variance τ^2^ to present heterogeneity across the network. Estimates of τ^2^ of approximately 0.04, 0.16, and 0.36 are considered to represent a low, moderate, and high degree of heterogeneity, respectively.[@ref24] We statistically evaluated inconsistency between direct and indirect sources of evidence globally (by fitting the inconsistency model) and locally (by calculating differences between direct and indirect estimates in closed loops),[@ref25] and provided P values in table C of appendix 3. We used forest plots to present the results of odds ratios and 95% confidence intervals. We presented the treatment hierarchy (fig C in appendix 2) of all endpoints according to cumulative rank probabilities.[@ref26] We assessed small study effects and potential publication bias with comparison-adjusted funnel plot symmetry.[@ref25] We also conducted a pairwise meta-analysis with both a random-effects model of DerSimonian and Laird's method and a fixed effect model of Mantel and Haenszel's method, providing the direct estimates (fig A in appendix 2). Analyses were performed in STATA version 14.0 (StataCorp).

To validate the robustness of the findings, we performed a sensitivity analysis by restricting long term DAPT to ≥18 months of DAPT, as well as applying a random effects Bayesian network meta-analysis to account for methodological and clinical heterogeneity across studies.[@ref27] We used Markov chain Monte Carlo methods with the GeMTC package (version 0.8-2) in R (version 3.4.4) to calculate odds ratios and 95% credible intervals. Three Markov chains were run simultaneously with 100 000 simulated draws after a burn-in of 50 000 iterations. Trace plots and the Brooks-Gelman-Rubin statistic were assessed to ensure convergence.[@ref28] We evaluated consistency with a node-splitting technique that compares the direct and indirect estimates for each comparison.[@ref29] Model fit was evaluated with the total residual deviance, which indicated good fit, if it approximated the number of data points (table D in appendix 3).

To further consider the effects of clinical presentations and stent technologies, we conducted subgroup analyses in the frequentist framework for patients with ACS and patients implanted with newer generation DES, by using published subpopulation data of the included trials.

Quality of evidence
-------------------

Additionally, we assessed the quality of evidence using the GRADE framework with GRADEpro GDT,[@ref30] which characterises the quality of a body of evidence based on the study design, risk of bias, inconsistency, indirectness, imprecision, and other considerations, for each outcome.[@ref31] [@ref32] The GRADE approach rates the evidence as high, moderate, low, and very low quality. We also calculated the absolute effects in each comparison for all endpoints.[@ref33]

Patient and public involvement
------------------------------

No patients or the public were involved in setting the research question or designing the study, nor were they involved in the outcome measures or implementation of the study. No patients were asked to advise on the interpretation or writing of the results. There were no plans to disseminate the results of the research to the study participants or relevant patient communities. It was not evaluated whether the studies included in the review had any patient involvement. It was not evaluated whether the studies included in the review had any patient involvement.

Results
=======

Characteristics of included studies and bias assessment
-------------------------------------------------------

[Figure 1](#f1){ref-type="fig"} shows that overall, 10 803 citations met the search criteria, and the full text of 59 potentially eligible articles was scrutinized. All available studies from trial registries were included in the database search, resulting in 17 studies of 18 parallel randomised controlled trials from 2010 to 2018 and including 46 864 participants (range 1259-9961 in each study).[@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref34] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] The shortest duration of DAPT was three months and the longest duration was 48 months. Overall, 13 234 participants were randomly assigned to short term DAPT, 18 473 to standard term DAPT, and 15 157 to long term DAPT. All randomised controlled trials reported full clinical and demographic characteristics ([table 1](#tbl1){ref-type="table"} and table A in appendix 3).
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###### 

Effects of treatment on outcomes in 17 studies

  Months of DAPT                           Participants   All cause mortality   Cardiac death   Non-cardiac death   Myocardial infarction   Definite or probable stent thrombosis   Stroke   Net adverse clinical events   Major bleeding   Any bleeding
  ---------------------------------------- -------------- --------------------- --------------- ------------------- ----------------------- --------------------------------------- -------- ----------------------------- ---------------- --------------
  **OPTIMA-C (Lee, 2018)**                                                                                                                                                                                                                  
  6                                        683            2                     1               1                   1                       0                                       0        NA                            1                NA
  12                                       684            3                     2               1                   1                       1                                       2        NA                            1                NA
  **I-LOVE-IT 2 (Han, 2016)**                                                                                                                                                                                                               
  6                                        909            11                    6               5                   41                      5                                       11       66                            11               50
  12                                       920            14                    7               7                   36                      2                                       13       60                            6                52
  **IVUS-XPL study (Hong, 2016)**                                                                                                                                                                                                           
  6                                        699            5                     3               2                   1                       2                                       6        15                            5                NA
  12                                       701            10                    5               5                   0                       2                                       3        14                            7                NA
  **ISAR-SAFE (Schulz-Schupke, 2015)**                                                                                                                                                                                                      
  6                                        1997           8                     NA              NA                  13                      5                                       7        29                            2                27
  12                                       2003           12                    NA              NA                  14                      4                                       5        32                            8                55
  **SECURITY (Colombo, 2014)**                                                                                                                                                                                                              
  6                                        682            8                     5               3                   16                      2                                       6        31                            4                5
  12                                       717            8                     3               5                   15                      3                                       2        27                            8                8
  **OPTIMIZE (Feres, 2013)**                                                                                                                                                                                                                
  3                                        1563           43                    29              14                  49                      13                                      5        93                            10               35
  12                                       1556           45                    32              13                  42                      12                                      5        90                            14               45
  **EXCELLENT (Gwon, 2012)**                                                                                                                                                                                                                
  6                                        722            4                     2               2                   13                      6                                       3        24                            2                4
  12                                       721            7                     3               4                   7                       1                                       5        21                            4                10
  **RESET (Kim, 2012)**                                                                                                                                                                                                                     
  3                                        1059           5                     NA              NA                  2                       2                                       6        NA                            2                5
  12                                       1058           8                     NA              NA                  4                       3                                       6        NA                            6                10
  **SMART-DATE (Hahn, 2018)**                                                                                                                                                                                                               
  6                                        1357           35                    18              17                  24                      15                                      11       NA                            6                35
  12.6 to 18                               1355           39                    24              15                  10                      10                                      12       NA                            10               51
  **NIPPON (Nakamura, 2017)**                                                                                                                                                                                                               
  6                                        1654           16                    NA              NA                  4                       2                                       7        34                            11               NA
  18                                       1653           7                     NA              NA                  1                       1                                       6        24                            12               NA
  **ITALIC (Didier, 2017)**                                                                                                                                                                                                                 
  6                                        926            11                    5               6                   12                      6                                       6        NA                            0                NA
  24                                       924            20                    5               15                  9                       3                                       7        NA                            4                NA
  **PRODIGY (Valgimigli, 2012)**                                                                                                                                                                                                            
  6                                        983            65                    NA              NA                  41                      15                                      14       NA                            6                34
  24                                       987            65                    NA              NA                  39                      13                                      21       NA                            16               73
  **OPTIDUAL (Helft, 2015)**                                                                                                                                                                                                                
  12                                       690            24                    NA              NA                  16                      1                                       7        52                            4                20
  48                                       695            16                    NA              NA                  11                      3                                       5        40                            4                18
  **DAPT Study (Mauri, 2014)**                                                                                                                                                                                                              
  12                                       4941           74                    47              27                  198                     65                                      43       NA                            26               137
  30                                       5020           98                    45              53                  99                      19                                      37       NA                            38               263
  **DES LATE (Lee, 2014)**                                                                                                                                                                                                                  
  12                                       2514           32                    19              13                  27                      11                                      21       74                            24               NA
  36                                       2531           46                    28              18                  19                      7                                       21       89                            34               NA
  **ARCTIC-Interruption (Collet, 2014)**                                                                                                                                                                                                    
  12                                       624            9                     NA              NA                  9                       3                                       4        NA                            1                3
  18 to 30                                 635            7                     NA              NA                  9                       0                                       6        NA                            7                12
  **REAL-ZEST LATE (Park, 2010)**                                                                                                                                                                                                           
  12                                       1344           13                    8               5                   7                       4                                       4        NA                            1                NA
  36                                       1357           20                    13              7                   10                      5                                       9        NA                            3                NA

DAPT=dual antiplatelet therapy; NA=not available

The risk of bias assessment was performed for each randomised controlled trial and summarised (table A in appendix 3). Most of the studies were in the lowest categories for risk of bias, random sequence generation (16/17, 94%), selective reporting (16/17, 94%), incomplete outcome data (15/17, 88%), and allocation concealment (13/17, 76%). A few studies were in the highest categories for risk of bias, blinding of participants and personnel (2/17, 12%), blinding of outcome assessment (4/17, 24%), and other bias (6/17, 35%). The category of unclear risk contained the most studies for other bias (10/17, 59%), blinding of participants and personnel (9/17, 53%), as well as blinding of outcome assessment (8/17, 47%).

Outcomes of network meta-analysis
---------------------------------

### All cause mortality, cardiac death, and non-cardiac death

We evaluated all studies reporting all cause mortality and 11 studies with a total of 32 826 participants reporting cardiac death. [Table 1](#tbl1){ref-type="table"} shows that we also deduced non-cardiac death from all cause mortality and cardiac death.

Although long term DAPT (\>12 months) resulted in more non-cardiac death than short term (≤6 months) DAPT (odds ratio 1.63, 95% confidence interval 1.03 to 2.59, τ^2^=0.02), all cause mortality and cardiac death showed no significant differences (1.18, 0.93 to 1.49, 0; 1.28, 0.88 to 1.86, 0). [Figure 2](#f2){ref-type="fig"} shows that standard term DAPT showed rates similar to those of short term DAPT for the three endpoints.
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### Ischaemic and haemorrhagic endpoints

[Table 1](#tbl1){ref-type="table"} shows that all studies reported myocardial infarction, definite or probable stent thrombosis, and major bleeding, and 11 studies with 31 194 participants reported any bleeding.

Compared with short term DAPT, long term DAPT decreased the risk of ischemia, myocardial infarction, and definite or probable stent thrombosis. Simultaneously, the risk of major bleeding and any bleeding (odds ratio 0.63, 95% confidence interval 0.46 to 0.86, τ^2^=0.17; 0.57, 0.34 to 0.95, 0.27; 1.78, 1.27 to 2.49, 0; 2.13, 1.46 to 3.10, 0.29) was increased. Standard term DAPT resulted in higher any bleeding than short term DAPT (1.39, 1.01 to 1.92, 0.29). [Figure 2](#f2){ref-type="fig"} shows that similar rates of myocardial infarction and definite or probable stent thrombosis were noted between standard term and short term DAPT.

### Stroke and net adverse clinical events

[Table 1](#tbl1){ref-type="table"} shows that all studies reported stroke and nine studies, with a total of 22 927 participants, reported net adverse clinical events. We noted that the three durations presented similar rates of these two outcomes.

Sensitivity analysis
--------------------

The SMART-DATE trial compared short term versus long term DAPT, which might weaken the discrimination among three arms.[@ref44] Thus, we excluded it to restrict the long term arm to ≥18 months of DAPT and generated a group of 16 studies with 44 152 patients. [Figure 3](#f3){ref-type="fig"} shows the results with more obvious differences, under both frequentist and Bayesian frameworks. Compared with short term DAPT, ≥18 months of DAPT resulted in higher rates of non-cardiac death (frequentist odds ratio 2.28, 95% confidence interval 1.35 to 3.86; Bayesian 2.34, 1.25 to 4.44), major bleeding (frequentist 1.79, 1.26 to 2.56; Bayesian 1.95, 1.28 to 3.39), and any bleeding (frequentist 2.46, 1.61 to 3.77; Bayesian 2.54, 1.48 to 4.63).
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According to fig B2 in appendix 2, differences also presented between ≥18 months versus standard term DAPT in non-cardiac death (frequentist odds ratio 1.74, 95% confidence interval 1.23 to 2.47; Bayesian 1.71, 1.05 to 2.76), any bleeding (frequentist 1.68, 1.15 to 2.47; Bayesian 1.74, 1.02 to 2.82), and major bleeding (frequentist 1.39, 1.03 to 1.88; Bayesian 1.43, 0.99 to 2.27). These results indicated that the risk of non-cardiac death and bleeding increased synchronously when the duration of DAPT was increased.

Other endpoints presented similar efficacy and heterogeneity as the 17 studies group ([fig 3](#f3){ref-type="fig"}, table C2 in appendix 3).

Subgroup analyses based on stent type and patient health
--------------------------------------------------------

Newer-generation DES improve mortality and ischaemic outcomes compared with first-generation DES,[@ref46] [@ref47] and patients with ACS have higher ischaemic risks than patients with stable coronary artery disease.[@ref48] [@ref49] Thus, we regarded the patients with the two conditions derived from subgroup or pooled analyses of pertinent randomised controlled trials respectively.

[Table 2](#tbl2){ref-type="table"} shows that 11 trials reported endpoints of newer-generation DES subgroup with 23 753 participants, and eight trials reported endpoints of ACS subgroup with 12 376 participants. In long term DAPT, higher risks of all cause mortality (odds ratio 1.99, 95% confidence interval 1.04 to 3.81), major bleeding (1.88, 1.03 to 3.45), and any bleeding (1.79, 1.28 to 2.50) were observed when compared with short term DAPT in the newer-generation DES subgroup, and merely an increased risk of any bleeding (1.73, 1.11 to 2.69) was noted in the ACS subgroup. [Figure 4](#f4){ref-type="fig"} shows that no significant difference was obtained for all endpoints between standard term and short term DAPT, in both subgroups.

###### 

Effects of treatments on outcomes in subgroups of patients

  Original study                     Subgroup characteristic                             Subgroup reference         Months of DAPT treatment   Total   All cause mortality   Myocardial infarction   Definite or probable stent thrombosis   Major bleeding   Any bleeding
  ---------------------------------- --------------------------------------------------- -------------------------- -------------------------- ------- --------------------- ----------------------- --------------------------------------- ---------------- --------------
  **Newer-generation DES**                                                                                                                                                                                                                                    
  OPTIMA-C (Lee, 2018)               BES/ZES                                             Lee, 2018[@ref7]           6                          683     2                     1                       0                                       1                NA
  12                                 684                                                 3                          1                          1       1                     NA                                                                               
  I-LOVE-IT 2 (Han, 2016)            BP-SES                                              Han, 2016[@ref8]           6                          909     11                    41                      5                                       11               50
  12                                 920                                                 14                         36                         2       6                     52                                                                               
  IVUS-XPL study (Hong, 2016)        EES                                                 Hong, 2016[@ref42]         6                          699     5                     1                       2                                       5                NA
  12                                 701                                                 10                         0                          2       7                     NA                                                                               
  SECURITY (Colombo, 2014)           ZES/BES/EES                                         Colombo, 2014[@ref37]      6                          682     8                     16                      2                                       4                5
  12                                 717                                                 8                          15                         3       8                     8                                                                                
  OPTIMIZE (Feres, 2013)             ZES                                                 Feres, 2013[@ref35]        3                          1563    43                    49                      13                                      10               35
  12                                 1556                                                45                         42                         12      14                    45                                                                               
  EXCELLENT (Gwon, 2012)             EES                                                 Gwon, 2012[@ref5]          6                          540     3                     9                       3                                       2                3
  12                                 539                                                 4                          6                          1       3                     9                                                                                
  SMART-DATE (Hahn, 2018)            EES/ZES/BES                                         Hahn, 2018[@ref44]         6                          1357    35                    24                      15                                      6                35
  12.6 to 18                         1355                                                39                         10                         10      10                    51                                                                               
  NIPPON (Nakamura, 2017)            BES                                                 Nakamura, 2017[@ref9]      6                          1654    16                    4                       2                                       11               NA
  18                                 1653                                                7                          1                          1       12                    NA                                                                               
  ITALIC (Didier, 2017)              EES                                                 Didier, 2017[@ref43]       6                          926     11                    12                      6                                       0                NA
  24                                 924                                                 20                         9                          3       4                     NA                                                                               
  PRODIGY (Valgimigli, 2012)         ZES/EES                                             Valgimigli, 2013[@ref50]   6                          492     25                    12                      1                                       25               NA
  24                                 496                                                 30                         16                         4       30                    NA                                                                               
  DAPT Study (Mauri, 2014)           EES                                                 Hermiller, 2016[@ref51]    12                         2358    26                    72                      16                                      7                30
  30                                 2345                                                49                         48                         6       21                    57                                                                               
  **Patient health**                                                                                                                                                                                                                                          
  ISAR-SAFE (Schulz-Schupke, 2015)   Acute coronary syndrome                             Lohaus, 2016[@ref52]       6                          794     5                     6                       2                                       1                3
  12                                 807                                                 7                          8                          2       2                     5                                                                                
  IVUS-XPL study (Hong, 2016)        Acute coronary syndrome with 2nd generation stent   Jang, 2018[@ref53]         3 to 6                     1119    9                     7                       6                                       4                9
  EXCELLENT (Gwon, 2012)                                                                                                                                                                                                                                      
  12                                 1097                                                11                         9                          4       6                     14                                                                               
  RESET (Kim, 2012)                                                                                                                                                                                                                                           
  SMART-DATE (Hahn, 2018)            Acute coronary syndrome                             Hahn, 2018[@ref44]         6                          1357    15                    24                      15                                      6                35
  12.6 to 18 months                  1355                                                10                         10                         10      10                    51                                                                               
  ITALIC (Didier, 2017)              Acute coronary syndrome                             Didier, 2017[@ref43]       6                          400     4                     7                       5                                       0                NA
  24                                 406                                                 9                          6                          3       2                     NA                                                                               
  PRODIGY (Valgimigli, 2012)         Acute coronary syndrome                             Costa, 2015[@ref54]        6                          733     56                    39                      5                                       6                3
  24                                 732                                                 52                         33                         10      9                     18                                                                               
  DAPT Study (Mauri, 2014)           Acute myocardial infarction                         Yeh, 2015[@ref55]          12                         1711    27                    88                      32                                      9                35
  30                                 1805                                                24                         39                         9       13                    76                                                                               

DAPT=dual antiplatelet therapy; NA=not available
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Therefore, long term DAPT might be associated with increased all cause mortality in patients implanted with newer-generation DES, and short term DAPT might be non-inferior to standard term DAPT independent of DES generation and clinical presentation.

Network coherence and quality of evidence
-----------------------------------------

There was no noticeable difference between direct and indirect estimates in closed loops that allowed the assessment of network coherence in all endpoints (table C in appendix 3). The total residual deviance for the outcomes of all endpoints (table D in appendix 3) suggested a good model fit in the sensitivity analysis under the Bayesian framework. We verified the convergence of chains visually in the trace plots and by inspecting the Brooks-Gelman-Rubin diagnostic statistic with values of approximately one.[@ref28]

A summary of the quality assessment of endpoints by the GRADE criteria was presented in table E in appendix 3. The quality of endpoints was determined to be moderate and high for most of the comparisons. Non-cardiac death and major bleeding were rated high.

Discussion
==========

Principal findings
------------------

In our meta-analysis, which included 17 studies and 46 864 patients, we analysed the comparative efficacy and safety of three durations of DAPT after PCI with DES. We applied frequentist and Bayesian frameworks in intention-to-treat populations to increase confidence in our findings.

In patients with all clinical presentations, firstly, long term DAPT led to a higher risk of non-cardiac death and major bleeding than short term DAPT in patients, and the discrimination was more noticeable when restricting long term DAPT to ≥18 months. Secondly, myocardial infarction and stent thrombosis showed no obvious difference between short term and standard term DAPT, and standard term DAPT increased the risk of any bleeding. Thirdly, the risk of non-cardiac death and bleeding increased synchronously with increasing durations of DAPT. Fourthly, all cause mortality, cardiac death, stroke, and net adverse clinical events presented similar risks for the three durations.

In both subgroups of newer-generation DES and patients with ACS, long term DAPT was associated with higher bleeding events than short term DAPT, and short term DAPT showed similar efficacy and safety to standard term DAPT. Long term DAPT resulted in increased all cause mortality compared with short term DAPT in the newer-generation DES subgroup.

Comparison with other studies
-----------------------------

Previous trials and pairwise meta-analyses, which were limited to two durations of DAPT as extended term or short term, failed to find disparate risks of mortality for different durations.[@ref56] [@ref57] Palmerini and colleagues conducted an individual patient data study showing variant ischaemic risks of three months of DAPT between patients with ACS and stable coronary artery diseases.[@ref11] However, the population of patients with ACS was 4758, which might affect the confidence in the conclusion. Another network meta-analysis studying the impacts of stent types and duration of DAPT, might be limited in clinical practice, owing to too many arms introduced.[@ref58]

In our pooled analysis, we studied short term, standard term, and long term DAPT in both the general population of coronary artery disease and subgroups of patients with newer-generation DES or ACS to evaluate durations of DAPT in a succinct way.

Short term versus long term DAPT
--------------------------------

NIPPON investigators reported that 18 months of DAPT seemed to incur less all cause mortality than six months of DAPT (7/1653 *v* 16/1654).[@ref9] However, a meta-analysis based on 10 randomised controlled trials concluded that a DAPT duration of more than one year was associated with increased mortality because of an increased risk of non-cardiovascular mortality.[@ref59] Another systematic review of 11 randomised controlled trials concluded that 18 to 48 months of DAPT showed no difference in all cause mortality compared with six to 12 months of DAPT.[@ref60]

Our results support that non-cardiac death, instead of non-cardiovascular death, occurred less frequently with short term DAPT than with long term DAPT, and this effect was more apparent when long term DAPT was restricted to ≥18 months. This finding indicates that vascular death (such as death caused by cerebrovascular disease, dissecting aneurysm, or other vascular diseases)[@ref61] might play a role in long term DAPT. We also found that the risks of non-cardiac death and bleeding increased synchronously with prolonged duration of DAPT; this finding is supported by a study that reported shorter durations of DAPT were associated with a lower risk of bleeding-related death than longer durations of DAPT.[@ref10] Additionally, long term DAPT was related to a higher risk of all cause mortality in patients implanted with newer-generation DES, compared with short term DAPT.

Short term versus standard term DAPT
------------------------------------

Randomised controlled trials have always concluded that short term DAPT was non-inferior to standard term DAPT.[@ref5] [@ref6] [@ref7] [@ref8] [@ref35] [@ref37] [@ref40] [@ref42] [@ref44] [@ref62] Piccolo's analysis of 38 919 patients reported that long term DAPT exposure showed increased major adverse cardiac and cerebrovascular events (MACCE) through 90 days after DAPT continuation which was not observed in \<12 months of DAPT.[@ref63] However, several studies showed that long term DAPT was associated with similar major adverse cardiac events and a higher risk of bleeding after PCI with DES compared with short term DAPT, regardless of diabetes diagnosis or sex.[@ref18] [@ref57] [@ref64]

We extracted data regarding net adverse clinical events, a pooled outcome including MACCE and major bleeding, and found no difference among the three durations, which is supported by Palmerini's individual patient data meta-analysis.[@ref11] In our analysis, the risk of bleeding was higher in standard term DAPT than in short term DAPT, and other endpoints (including ischemia-related and death-related endpoints) were noted with similar rates. Thus, compared with standard term DAPT, short term DAPT might present superiority with higher safety and similar efficacy in the general population of coronary artery disease. However, in subgroups of patients with newer-generation DES or ACS we did not observe a noticeable difference between short term and standard term DAPT for all endpoints.

Strengths and limitations of this study
---------------------------------------

The main strength of our study is that we divided the durations of DAPT into three categories with short term (≤6 months) DAPT as a control. With a combination of direct and indirect comparisons, network meta-analysis often leads to substantially more precise summary results.[@ref19] The frequentist results were confirmed in in Bayesian framework. Thus, these findings have robust statistical consistency. Furthermore, although the reviewed randomised controlled trials covered the past years of research, heterogeneity was low across trials. We tried our best to extract original data form each study and performed post hoc subgroup analyses according to these data.

This study has several limitations. Firstly, we primarily evaluated durations of DAPT based on clopidogrel, so the conclusion might vary when applying other P2Y~12~ inhibitors such as prasugrel and ticagrelor. Secondly, we performed analyses of outcomes from different trials with pooled definitions. Thirdly, several endpoints were not reported by a few trials, like cardiac death (RESET, OPTIDUAL, and NIPPON trial reported cardiovascular death only), which might partly explain the slight divergence between results under the frequentist and Bayesian frameworks.

Policy implications
-------------------

Standard term (12 months) DAPT was the recommended duration for most patients in guidelines published between 2011 and 2014. However, some factors are important in determining the duration of DAPT, such as whether a patient has ACS, type of DES, and bleeding and ischaemic risks.[@ref3] [@ref65] Therefore, the current American College of Cardiology/American Heart Association guideline presented critical questions to choose among three to six months, 12 months, and more than 12 months of DAPT according to variant factors.[@ref3]

According to our analysis, three to six months of DAPT with clopidogrel presented similar efficacy and safety to 12 months of DAPT in patients treated with newer-generation DES and patients with ACS, without considering personal haemorrhagic profiles. Though the guidelines recommended six months of DAPT to patients with ACS only when high bleeding risks were considered.[@ref2] [@ref3] Moreover, in a broader spectrum including patients with ACS and stable coronary artery disease, three to six months of DAPT was associated with higher safety than 12 months of DAPT. The present findings suggest additional benefit of three to six months of DAPT.

Additionally, compared with three to six months, long term DAPT was associated with higher all cause mortality in patients implanted with newer-generation DES, as well as higher non-cardiac death in the general population of patients with coronary artery disease. Therefore, it might be reasonable to apply long term DAPT to a narrower spectrum of patients.

Conclusion
----------

Our comprehensive network meta-analysis provides evidence that short term DAPT (with clopidogrel) could be considered for most patients after PCI with DES. Long term DAPT resulted in more death and bleeding-related events, and standard term DAPT presented similar efficacy and safety. Further studies, such as prespecified randomised controlled trials of patients with newer-generation DES and ACS are required to validate the rationality of short term DAPT after PCI with DES.

### What is already known on this topic

1.  A longer duration of dual antiplatelet therapy (DAPT) for patients receiving DAPT after drug-eluting stent (DES) implantation is associated with an increased risk of bleeding, and a shorter duration of DAPT is associated with an increased risk of ischemia

2.  Pairwise meta-analyses are limited to two durations of DAPT (short term and long term) and network meta-analyses are inclined to evaluate inappropriate arms

### What this study adds

1.  Short term DAPT (\<6 months) is recommended for patients implanted with DES and treated with clopidogrel, in both the general population of patients with coronary artery disease and subgroups of patients with newer-generation DES or acute coronary syndrome

2.  Long term DAPT (\>12 months) resulted in more death and bleeding-related events

3.  Standard term DAPT (12 months) showed similar efficacy and safety compared with short term DAPT
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